AMEDD Advanced Medical Technology Initiative (AAMTI)
AAMTI EIF Timeline (FY20):*11 JAN - 15 APR 2019, EIF Pre-proposal submissions accepted
1 JUL - 9 AUG 2019, Opening Date for EIF Full Proposal Submissions
30 SEP 2019, EIF Award Notifications
* Subject to change
AMEDD Advanced Medical Technology Initiative (AAMTI) Program facilitates bottom-up technology innovation while simultaneously informing top-down acquisition throughout Army Medicine. Program execution encompasses small funding investments at the facility/individual level in two distinct categories: Rapid Innovation Funding (RIF) and Extended Innovation Funding (EIF) for which the period of performance for each category is limited to 6 and 18 months respectively.
Identification, exploration, and demonstration of key technologies and enabling biomedical principles required to overcome technological barriers that are medically and militarily unique.
AAMTI projects should enable smarter acquisition decisions that positively affect the enterprise through:
- Demonstrating medical technologies and documenting their impact on cost, access, quality, and safety of care and medical readiness through a bottom-up (provider/MTF level) approach.
- Provide senior MEDCOM leadership with medical tech-surveillance capability through feedback loops.
Submissions to the AAMTI program should be innovative, non-duplicative, acquisition sensitive, collaborative and implementable within AAMTI funding timeframe.
Each submission will be evaluated based upon the following criteria: innovative concept, military relevance, metrics for success and potential return on investment (ROI). Those innovators whose proposals are deemed to be of greatest interest will be invited to submit a full proposal, which will be evaluated by the AAMTI Full Proposal Review Panel. Funding is made available on a year by year basis and is dependent on Command approval for continuation.
Questions concerning the preparation of submissions can be emailed to the AAMTI Program Management office at email@example.com.